A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis (ENHANCE)

Trial Profile

A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis (ENHANCE)

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Fampridine (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ENHANCE
  • Sponsors Biogen
  • Most Recent Events

    • 27 Jun 2017 Results assessing the magnitude of mean change in MSWS-12 score over 24 weeks, presented at the 3rd Congress of the European Academy of Neurology
    • 24 May 2017 According to a Biogen media release, based on the results from this study, the European Commission (EC) has granted a standard marketing authorization for FAMPYRA (prolonged-release fampridine tablets) for walking improvement in people with multiple sclerosis (MS).
    • 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top